On July 11, 2023, Crossbow Therapeutics, Inc. closed the transaction. The company has issued 32,639,874 series A preferred shares at an issue price of $1.3 per share for the gross proceeds of $42,431,836.2 in its second and final tranche, the company has issued total 61,538,462 series A preferred shares for gross proceeds of $80,000,000.6 in the transaction. The transaction was co-led by MPM Asset Management, L.L.C., and Pfizer Venture Investments LLC, and included participation other new investors, Polaris Venture Partners, Inc., BVF Partners L.P., Eli Lilly and Company, Mirae Asset Venture Investment Co., Ltd., and Mirae Asset Capital Co., Ltd. The round is raised at a post-money valuation of $112,545,580.
Mirae Asset Venture Investment Co., Ltd.
Equities
A100790
KR7100790005
Investment Management & Fund Operators
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5,720 KRW | -0.35% | +0.53% | -1.04% |
24/04 | Dalpha Inc. announced that it has received KRW 12 billion in funding from a group of investors | CI |
17/04 | Upstage Attracts Investments Worth 100 Billion Won in Latest Fundraising | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
5,720 KRW | -0.35% | +0.53% | 219M | ||
771.6 USD | -1.96% | +0.14% | 709B | ||
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.04% | 219M | |
+14.46% | 3.05B | |
+12.82% | 2.06B | |
+8.43% | 1.51B | |
-11.54% | 1.2B | |
+11.49% | 756M | |
+28.93% | 570M | |
-4.17% | 503M | |
+29.04% | 466M | |
+3.90% | 309M |
- Stock Market
- Equities
- A100790 Stock
- News Mirae Asset Venture Investment Co., Ltd.
- Crossbow Therapeutics, Inc. announced that it has received $80.000001 million in funding from a group of investors